Serine racemase (SR) is a pyridoxal 5 0 -phosphate (PLP)-containing enzyme that converts l-serine to d-serine, an endogenous co-agonist for the N-methyl-daspartate receptor (NMDAR) subtype of glutamate ion channels. SR regulates d-serine levels by the reversible racemization of l-serine to d-serine, as well as the catabolism of serine by ,-elimination to produce pyruvate. The modulation of SR activity is therefore an attractive therapeutic approach to disorders associated with abnormal glutamatergic signalling since it allows an indirect modulation of NMDAR function. In the present study, a 1.89 Å resolution crystal structure of the human SR holoenzyme (including the PLP cofactor) with four subunits in the asymmetric unit is described. Comparison of this new structure with the crystal structure of human SR with malonate (PDB entry 3l6b) shows an interdomain cleft that is open in the holo structure but which disappears when the inhibitor malonate binds and is enclosed. This is owing to a shift of the small domain (residues 78-155) in human SR similar to that previously described for the rat enzyme. This domain movement is accompanied by changes within the twist of the central four-stranded -sheet of the small domain, including changes in the 'angles of all three residues in the C-terminal -strand (residues 149-151). In the malonate-bound structure, Ser84 (a catalytic residue) points its side chain at the malonate and is preceded by a six-residue -strand (residues 78-83), but in the holoenzyme the -strand is only four residues (78-81) and His82 has 'values in the -helical region of the Ramachandran plot. These data therefore represent a crystallographic platform that enables the structure-guided design of small-molecule modulators for this important but to date undrugged target. research communications Acta Cryst. (2020). F76, 65-73 Koulouris et al. Human serine racemase 71 research communications Acta Cryst. (2020). F76, 65-73 Koulouris et al. Human serine racemase 73
Introduction
N-Methyl-d-aspartate receptors (NMDARs) are a subtype of ionotropic glutamate receptors that are highly expressed in the central nervous system (CNS) and are involved in the excitatory synaptic transmission and synaptic plasticity that form the basis of many critical CNS functions (Traynelis et al., 2010) . Glutamatergic and more specifically NMDAR dysfunction has been implicated in various CNS disorders, including Alzheimer's disease (Zá dori et al., 2014; Balu et al., 2019) , amyotrophic lateral sclerosis (ALS; Paul & de Belleroche, 2014) , neuropathic pain (Petrenko et al., 2003) , schizophrenia (Howes et al., 2015) and major depressive disorder (Niciu et al., 2014) . Most nonselective, direct NMDAR antagonists (such as ketamine) that have shown efficacy at relieving symptoms of neuropathic pain (Zhou et al., 2011) and treatment-resistant depression (TRD; Daly et al., 2019; Vasilescu et al., 2017) Schatzberg, 2019) . Hence, indirect or subtype-specific modulators of NMDAR function offer the potential to have reduced side effects relative to nonselective antagonists. One approach is to target the NMDAR co-agonist d-serine, which is required for the activation of NMDARs via binding to the glycine modulatory site, so-called because glycine is an alternative endogenous co-agonist (Kleckner & Dingledine, 1988) . The neuroanatomical distribution suggests that d-serine is primarily localized to the forebrain, with a distribution that mirrors that of the GluN2A-and GluN2B-containing subtypes of NMDAR, while glycine is predominantly located in the hindbrain and brainstem, indicating a potentially selective avenue for modulating glutamate neurotransmission in the CNS (Papouin et al., 2012) . The critical role of d-serine has been described in neuropsychiatric conditions including schizophrenia (Tsai et al., 1998; Hashimoto et al., 2003; Labrie et al., 2012) , depression (Malkesman et al., 2012; Otte et al., 2013) and Alzheimer's disease (Hashimoto et al., 2004; Wu et al., 2004; Madeira et al., 2015) . The recent approval of esketamine, an enantiomer of racemic ketamine, as a nasal spray for treatment-resistant depression Schatzberg, 2019; Swainson et al., 2019; Fedgchin et al., 2019) demonstrates the therapeutic value of targeting NMDARs.
Serine racemase (SR) is a pyridoxal 5 0 -phosphate (PLP)containing enzyme that converts l-serine to d-serine (Wolosker et al., 1999) ; therefore, inhibitors of SR that reduce the production of d-serine are hypothesized to have therapeutic benefits in disorders associated with NMDAR hyperfunction (Coyle & Balu, 2018) . Almost all endogenous d-serine is produced by SR, as demonstrated by the observation that SR-knockout mice have an 80-90% reduction in d-serine levels (Balu et al., 2013) . Several groups have tried to identify new SR inhibitors that are potent, selective and structurally distinct from the many well described amino-acid analogues, but overall there has been relatively little progress (Jirá sková -Vaníčková et al., 2011; Beato et al., 2015; Vorlová et al., 2015; Watanabe et al., 2016; Mori et al., 2017) . One of the more promising approaches identified a series of dipeptidelike inhibitors with a clear structural motif and slow-binding kinetics (Dixon et al., 2006) , which later provided the query molecule for an in silico screen (Mori et al., 2014) . The resulting amide inhibitors and halogen-substituted derivatives showed improved inhibitory activity (compared with classical SR inhibitors), binding affinity and ligand efficiency, but limited potency, with reported IC 50 values of 0.28, 0.27 and 0.14 mM for the best compounds (Mori et al., 2017) . Overall, there are a negligible number of drug-like SR inhibitors and none that have been confirmed by crystallography.
X-ray crystal structures of mammalian SR were first published for the rat holoenzyme (1.8 Å resolution) and the rat and human malonate (an orthosteric inhibitor)-bound complexes (1.9 and 1.5 Å resolution), and more recently for the wild-type human holoenzyme (1.8 Å resolution) (Takahara et al., 2018; Smith et al., 2010) . SR is organized as a dimer, with each monomer comprised of a large domain containing the essential PLP cofactor covalently bound to Lys56 and a small domain that undergoes a ligand-induced reorientation upon binding at the domain interface (Smith et al., 2010) . The organization of the domain boundaries is described as follows for the human SR-malonate complex (PDB entry 3l6b; Smith et al., 2010) : the small domain (residues 55-151) contains a central four-stranded -sheet (residues 149-151, 78-83, 101-108 and 124-128) and four -helices (residues 55-66, 85-98, 111-121 and 131-147) , and the large domain (residues 1-68 and 157-340) contains a seven-stranded twisted -sheet surrounded by ten -helices.
PLP-dependent enzymes can be categorized as fold types I-IV, according to the similarity of their secondary structure (Jansonius, 1998) . SR belongs to the fold type II family, along with its closest homologue serine dehydratase (SDH). SDH is a mammalian enzyme that catalyses the dehydration of l-serine to pyruvate and ammonia, and shares 23% sequence identity with SR. Proteins in this group have two domains and each contains a -sheet core surrounded by -helices. Accordingly, the small domain of SDH consists of a central four-stranded -sheet surrounded by four -helices (Yamada et al., 2003; Sun et al., 2005) , and corresponds to residues 55-151 of SR. In the original crystal structure paper, Smith and coworkers defined the small domain as residues 78-155, and did not include helix 3 (55-66) in the small domain because it precedes a mobile hinge region (residues 69-77) and is not involved in the rearrangement of the small domain (Smith et al., 2010) . Further, their definition of a flexible loop region connecting both domains comprised of residues 68-77 and 145-149 (Smith et al., 2010) is somewhat problematic as residues 145-149 are defined as being within the small domain and are before the final -strand of the central -sheet.
In the present study, we have determined the structure of the holo form of human SR and used this in structural comparisons with the previously published human malonatebound complex. We have used the more soluble Cys2Asp, Cys6Asp mutant (Smith et al., 2010;  Section 2) as this construct improves the solubility during the purification process, while producing no significant structural changes at the N-terminus when compared with wild-type protein (PDB entry 5x2l; Takahara et al., 2018) . Moreover, we have sought to clarify the ambiguity regarding the domain-boundary definitions of SR, particularly in the context of ligand-induced small domain rearrangement. A more developed understanding of the conformational changes that occur upon malonate binding may further inform and enable strategies, such as structureguided drug design, for the development of novel inhibitors of SR with more drug-like properties.
Materials and methods

Macromolecule production
The pET-24a vector containing a C-terminal polyhistidine (His 6 ) tag and two cysteine-to-aspartate point mutations (Cys2Asp, Cys6Asp) to improve solubility during the purification process (Smith et al., 2010) and improve the overall yield (unpublished observations) was chemically transformed into Escherichia coli BL21 CodonPlus(DE3)-RIL cells, and research communications plated onto LB agar plates (50 mg ml À1 kanamycin and 35 mg ml À1 chloramphenicol) for overnight incubation at 37 C. Pre-cultures grown overnight in LB from a single colony at 37 C were used to inoculate 8 Â 1 l LB medium supplemented with 50 mg ml À1 kanamycin, 34 mg ml À1 chloramphenicol and 0.01% pyridoxine (the enzyme contains PLP as a cofactor). The cells were grown at 37 C to an optical density at 600 nm (OD 600 ) of 0.6, at which point gene expression was induced with 0.5 mM isopropyl -d-1-thiogalactopyranoside (IPTG) and cell growth was continued for a further 16-18 h at 25 C. The cells were harvested by centrifugation at 6500g for 20 min at 4 C and stored at À80 C.
The cell pellet was solubilized and lysed by sonication while on ice and the lysate was then clarified at 25 000g for 60 min at 4 C. The supernatant was loaded onto a TALON column for initial purification by immobilized-metal affinity chromatography via interaction of the SR His tag with the nickelcontaining beads of the TALON resin. The protein-containing fractions (as determined by SDS-PAGE) were loaded onto a Superdex 200 (26/60) column equilibrated with buffer consisting of 20 mM Tris pH 8.0, 100 mM NaCl, 5 mM DTT, 50 mM PLP, 1 mM MgCl 2 , 10% glycerol. The SR-containing fractions (as determined by SDS-PAGE) were pooled and concentrated to 15 mg ml À1 before being flash-frozen in liquid nitrogen and stored at À80 C. The protein concentration was determined by UV spectrophotometry at 280 nm using a molar extinction coefficient of 29 910 M À1 cm À1 and a molecular weight of 37.4 kDa. The protein yield was approximately 3 mg per litre of culture and the purified protein had a purity of >95%. Macromolecule-production information is summarized in Table 1 .
Crystallization
Human holo SR was crystallized by the sitting-drop vapourdiffusion method. A reservoir solution consisting of 15% PEG 3350, 100 mM bis-Tris pH 6.5, 250 mM MgCl 2 was mixed with the protein solution (6.5 mg ml À1 SR and 5 mM DTT) in a 1:1 ratio and equilibrated at 20 C. Crystals appeared within 48 h and grew to full size ($50 mm) within seven days. The crystal used for the diffraction experiment was cryoprotected by sequential soaking in reservoir solution supplemented with 10%, 20% and 30% glycerol prior to data collection. Crystallization information is summarized in Table 2 .
Data collection and processing
An X-ray data set was collected from a single cryocooled crystal on beamline I03 at the Diamond Light Source synchrotron (Table 3) .
Structure solution and refinement
The structure was solved by molecular replacement using the crystal structure of the rat SR holoenzyme (Smith et al., 2010 ; the rat holoenzyme was used because structure solution occurred prior to the deposition of PDB entry 5x2l) and was refined with REFMAC5 and phenix.refine (Adams et al., 2010) four subunits in the asymmetric unit contained residues A4-A325, B4-B326, C3-C325 and D4-D325. Towards the end of the refinement, difference maps clearly showed electron density for a second position for the -strands in the central -sheet of the small domain in the C subunit (the small domain of human SR is defined as residues 78-155). The small domain from the C subunit (residues C74-C152) was rigid-body fitted into the difference map in Coot, and the new position (and the original position) were refined with occupancies in steps of 0.1 (0.1/0.9, 0.2/0.8 etc.). Lower R factors (and R free ) suggested that the occupancy of the alternate 'new' position was approximately 0.3 (and that of the original position was 0.7). There is some variability in the position of the small domain relative to the large domain when all four subunits are compared ( Supplementary Fig. S1 ).
Across the four chains in the asymmetric unit (A, B, C and D), the overall ordering of the residues was reasonable, with exceptions at the N-terminus (residues 1-3) and C-terminus (residues 326-340). The small domains (residues 78-151) appear to be more mobile, with higher temperature factors (57.1, 100.4, 76.9 and 66.4 Å 2 for the small domains from chains A, B, C and D, respectively, compared with 34.9, 58.4, 53.7 and 38.6 Å 2 for the corresponding large domains). The flexible loop region (residues 66-77) is complete and well defined only in chain A, which is likely to be an effect of crystal packing. The Ramachandran plot reveals good stereochemistry and negligible steric hindrances between atoms of the polypeptide backbone, with 99.6% of residue angles falling within the allowed regions and 96% within favoured regions (Table 4 ).
Structure analysis
Secondary structures were calculated with the PDBSUM server (Laskowski et al., 2018) , including HERA plots of secondary structure (Hutchinson & Thornton, 1990) . The secondary structure of the A subunit from our 1.89 Å resolution holoenzyme structure (PDB entry 6slh), as calculated with the PDBSUM server, was manually checked against electron density in Coot (Emsley et al., 2010) . This secondary structure was compared with that defined in the PDB headers of the 1.5 Å resolution human SR structure in complex with malonate (PDB entry 3l6b; Smith et al., 2010) and the 1.81 Å resolution crystal structure of wild-type SR (PDB entry 5x2l; Takahara et al., 2018) . The PDBSUM server definitions of secondary structure for PDB entries 3l6b and 5x2l were also checked (see Supplementary Table S1 for definitions and comparisons of secondary-structure elements). This analysis defined the positions of the ten -strands (1-10), 12 -helices (1-12) and five 3 10 -helices in our structure ( Supplementary Table S1 ). We note that although serine dehydratase belongs to the same overall fold type as SR, it lacks the N-terminal helix of SR and its C-terminal helix is an -helix rather than the 3 10 -helix often seen in SR structures ( Supplementary Table S1 ).
Secondary-structure definitions were inserted into the PDB headers before drawing structures with PyMOL (v.1.5.0.4; Schrö dinger). The Kleywegt (Ramachandran) plots (Kleywegt & Jones, 1996) were drawn in Coot (Emsley et al., 2010) . 'angles were calculated with the CCP4 program ANGLES and are presented in Supplementary Table  S2 .
The small domain is defined as residues 78-155 and the large domain as residues 1-68 and 156-316. R.m.s. fits were calculated with LSQKAB (Winn et al., 2011) for all C atoms or subsets of C atoms between the A subunit of our new 1.89 Å resolution human SR structure and the previously determined structure in complex with malonate (PDB entry 3l6b) and holo structure in a different cell (PDB entry 5x2l) (see Supplementary Table S3 ). In the two holo structures the large and small domains are in roughly the same position, whereas in the complex with malonate the small domain is in a different position with respect to the large domain.
Results and discussion
Human SR holoenzyme structure
The crystal structure of the human SR holoenzyme was determined to a resolution of 1.89 Å in space group P2 1 and reveals the large domain (residues 1-68 and 156-316) and the small domain (residues 78-155) (Fig. 1a) (residues 1-68 and 157-340) in that we do not include the C-terminal 3 10 -helix (residues 319-325) and subsequent disordered residues. The recently published holoenzyme crystal structure of wild-type human SR (PDB entry 5x2l; Takahara et al., 2018) , which did not have the two N-terminal mutations Cys2Asp and CysC6Asp (see Section 2.1), has a very similar structure at the N-terminus. However, PDB entry 5x2l is shorter at the C-terminus (the last residue is 317) and does not have the C-terminal 3 10 -helix (see Supplementary Table S1 for a description of the secondary-structural elements used in this paper). Regardless of some local structural differences, the overall structures of PDB entries 6slh and 5x2l superpose well, with a C r.m.s.d. of 0.55 Å . The C-terminal helix (residues 319-325) of PDB entry 6slh is located at the dimer interface and appears to have some degree of flexibility, which may reflect a role in dimerization and stabilization of the protein complex. Indeed, the C-terminal 3 10 -helices are in close proximity to each other in chains A/C and B/D, and the interfaces of each pair of helices are lined with hydrophobic residues (Leu319, Thr320, Ile323 and Val326) that indicate the presence of dimerizing hydrophobic interactions. It has been suggested that the activity of SR may be regulated by interactions of its C-terminal residues with a PDZ domain from GRIP (Baumgart et al., 2007) .
In accordance with the characteristics of fold type II PLPdependent enzymes, our SR holoenzyme structure reveals a small domain with a central -sheet consisting of four parallel -strands (residues 78-81, 101-108, 124-128 and 149-151) flanked by two -helices on one side (residues 85-98 and 111-121) and one -helix (residues 131-146) on the other side. The large domain has a six-stranded -sheet core surrounded by -helices, and this domain arrangement is conserved between the malonate complex (PDB entry 3l6b) and our holoenzyme structure. A magnesium ion resides in the divalent cationbinding site, where it is coordinated by three buried waters, two acidic side chains (Glu210 and Asp216) and the research communications Overall comparison of the new holo human SR structure with that of a malonate complex (PDB entry 3l6b). (a) One human SR monomer from the 1.89 Å resolution holo structure. Each subunit has a large domain (dark blue) and a small domain (cyan). The C-terminal 3 10 -helix is shown in grey. The essential cofactor PLP covalently bound to Lys56 is shown in sphere representation. Superposition of the small domains of human SR structures. (a) The small domain (cyan) from the 1.89 Å resolution human SR structure contains secondary-structural elements labelled -3, -4, -4, -5, -5, -6 and -6. Also shown are main-chain hydrogen bonds (dark blue), the C-terminal 3 10 -helix (dark grey) and the 67-77 loop (dark grey). The Ser84 side chain (modelled in two rotamers) is shown in stick representation. (b) PLP attached to Lys56 drawn with MarvinSketch using the most likely tautomer at pH 7.0 (there are 14 possible tautomers between pH 4 and 10). (c) The human SR subunit from a structure with malonate (PDB entry 3l6b) is shown with the small domain in yellow and the large domain in light green. The Ser84 side chain is shown in stick representation pointing at malonate (orange sticks). Main-chain hydrogen bonds are shown in orange. main-chain carbonyl of Ala214, thus helping to stabilize protein folding and increase maximal activity (De Miranda et al., 2002; Bruno et al., 2017) . While the domain structure and most secondary-structural elements are conserved between SR and SDH, SDH lacks the N-terminal -helix and has a Cterminal -helix, rather than the C-terminal 3 10 -helix seen in some human SR structures ( Supplementary Table S1 ).
The small domain is in an 'open' position in the holo structure
Comparing the structures of holo (Fig. 1a ) and malonatebound ( Fig. 1b ) human SR using a superposition based on residues from the large domains showed a relative large shift of most of the small domain ( Fig. 1c ). There is a striking difference between the accessibility of the active site in the two structures. In the malonate-bound form (Figs. 1b and 1d ) the small domain is positioned tight against the large domain to form a 'closed' structure in which the catalytic site is inaccessible to solvent; notably, helices 5 and 6 shift towards PLP in the large domain by distances of about 5.5 and 8 Å , respectively. In the holoenzyme structure, the high degree of mobility of the small domain and flexible loop region is shown by the distance between the two domains, creating an 'open' position large enough to allow the binding of an amino acid, small molecule or compound.
When malonate is bound in the active site ( Fig. 1d ) it forms hydrogen bonds between its two carboxylic acid groups and the surrounding residues: the hydroxyl groups of Ser84 and Ser242, the amino groups of Ser84 and His87 and the side chain of Arg135 (Fig. 1d ). The dual carboxylic acid nature of malonate allows it to induce a conformational shift linking the large domain and Ser84, the key catalytic site residue located in the small domain. In a proposed mechanism of l-serine isomerization, PLP and l-serine are linked by a protonated Schiff base, and PLP then deprotonates l-serine to form a planar intermediate. Ser84 is moved into position via a ligandinduced shift on the opposite side of the PLP ring plane to donate a proton from its hydroxyl group and thus invert the stereochemistry of l-serine to d-serine (Yoshimura, 2008; Goto et al., 2009) .
The commonly accepted reaction mechanism of mammalian SR is based on data from bacterial enzymes and comparisons between human, rat and yeast orthologues (Goto et al., 2009; Smith et al., 2010) . The major structural change between human holo and malonate-bound SR described here further supports the existence of an analogous mechanism for l-serine isomerization in the human enzyme. Moreover, the 'open' conformation of the human SR holoenzyme suggests that the active site and key catalytic residues are accessible to small molecules and compounds, and indicates that SR is structurally enabled for drug-discovery efforts and in silico screening.
Conformational flexibility with the small domain of human SR
A superposition of holo ( Fig. 2a ) and malonate-bound (Fig. 2c) human SR based on residues from the small domains (residues 78-155) show that not all residues within the small domain of human SR 'move' with the small domain. Notably, the 4 helix (residues 85-99) and residues at the C-terminal end of the domain (residues 153-155) do not move with the rest of the small domain but seem to remain relatively static with regard to the large domain (Fig. 1c) . Thus, we have defined a small mobile subdomain (residues 78-81 and 101-148) which appears to be linked to the rest of SR by four Figure 3 Conformational flexibility within the small domain of the human SR structure. (a) Main-chain atoms from the small domain of human SR, close to Ser84, are shown with N atoms in blue, O atoms in red, C atoms in cyan for the holo structure and yellow for the malonate-bound structure (PDB entry 3l6b), and main-chain hydrogen bonds as dashed blue or orange lines. The small domains are superposed as in Fig 2(c) . The loop connecting the C-terminus of 3 to the N-terminus of 4 has a different conformation, and the 4 helix from the small domain is not well superposed. (For clarity, only the side chains of His82 and Ser84 are shown. Note how the carbonyl O atoms of His82, which are ringed, are pointing in different directions.) (b) A Kleywegt plot comparing the small domain of holo SR (subunit D) with that in a malonate-bound structure (PDB entry 3l6b). The plot shows arrows between the same residue in the two structures. Residues that have large differences in 'are labelled (blue for holo '-, orange for malonate '-). The 'angles in this region are presented in Supplementary Table S2. flexible hinge regions (residues 68-77, 82-85, 99-101 and 149-151) , which were defined based on further analysis of the small domain ( Fig. 3) . Our data show that the loop that contains Ser84 undergoes a dramatic change in conformation between the holo and ligand-bound structures (Fig. 3a) , with two residues, His82 and Gly85, having very different conformations (Fig. 3b) . A comparison of 'angles ( Supplementary  Table S2 ) demonstrates that not only are there dramatic changes in the 'angles of His82 and Gly85, but that there is a consistent change in the 'angles of the three residues in the final -strand of the small domain (residues 149-151; Supplementary Table S2 ). This -strand (residues 149-151), acting as a flexible hinge region, is relatively well superposed whether the superposition is based on the large domain ( Fig. 1c ) or the small domain ( Fig. 2c ). Furthermore, a significant change in the conformation of residues 82-85 ( Fig. 3) indicates that this is an additional loop region, which may function to prevent any catalysis occurring until the substrate is fully captured in an enclosed active site.
Discussion
When large structural movements take place within a single globular structural domain (for example between the GDPand GTP-bound forms of the small GTPase ARF; Goldberg, 1998) , subdivision of the structural domain into subdomains that 'move' relative to each other in different states of the protein may become relevant. We have analysed secondaryand tertiary-structure elements in our human holoenzyme SR structure and in a malonate complex of SR (PDB entry 3l6b) to define 'moving' and 'relatively static' subdomains within the small domain of human serine racemase, and we show that only part of the small domain moves upon the binding of malonate. While the crystal structure presented here appears to have high global structural homology to previous SR structures (PDB entries 5x2l and 3l6b), our observations regarding the movement of the small domain subdomain and the presence of four flexible hinge regions differs from previous assertions in that the ligand binding induced movement of the entire small domain flanked by two loop regions (Smith et al., 2010) . Structural knowledge of SR subdomain rearrangement is important for in silico drug design, pharmacophore modelling and screening, and provides additional information for determining how conformational changes of the hinge regions and subdomain alter binding in the active site.
